Cargando…
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
Real‐world data and patient‐level data from completed randomized controlled trials are becoming available for secondary analysis on an unprecedented scale. A range of novel methodologies and study designs have been proposed for their analysis or combination. However, to make novel analytical methods...
Autores principales: | Eichler, Hans‐Georg, Koenig, Franz, Arlett, Peter, Enzmann, Harald, Humphreys, Anthony, Pétavy, Frank, Schwarzer‐Daum, Brigitte, Sepodes, Bruno, Vamvakas, Spiros, Rasi, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158212/ https://www.ncbi.nlm.nih.gov/pubmed/31574163 http://dx.doi.org/10.1002/cpt.1638 |
Ejemplares similares
-
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
por: Eichler, Hans‐Georg, et al.
Publicado: (2020) -
Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?
por: Eichler, Hans‐Georg, et al.
Publicado: (2020) -
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019) -
Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023) -
Pharmacovigilance 2030: Invited Commentary for the January 2020 “Futures” Edition of Clinical Pharmacology and Therapeutics
por: Arlett, Peter, et al.
Publicado: (2019)